GMAB News and Press, Genmab A/S From 05/14/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (NYSE: JNJ ) stock is up for 2022 in a down market Credit goes to its medical devices and anti-cancer drug Darzalex JNJ’s dividend has been rising for six decades, making it a safe st...

Multiple epcoritamab (DuoBody ® -CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several abstracts evaluating Genmab owned and partnered programs accepted for pr...

The following slide deck was published by Genmab A/S in conjunction with their 2022 Q1 earnings call. For further details see: Genmab A/S 2022 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q1 2022 Earnings Call May 11, 2022 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q1 2022 Earnings Call Transcript

Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Peter Virgil - Citigroup James Gordon - JPMorgan Wimal Kapadia - Bern...

Genmab A/S press release (GMAB): Q1 Operating Profit of DKK 514M. Revenue of DKK 2.12B. FY22 revenue guidance in the range of DKK 11B-12B. Operating profit guidance in the range of DKK 3.2B-4.8B. For further details see: Genmab Q1 Operating Profit of DKK 514M, Revenue of DKK 2.12B

Genmab A/S (GMAB) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is $0.19 (-98.9% Y/Y) and the consensus Revenue Estimate is $294.12M (-81.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions ...

The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but positive price gain in the past three years, is an apparently visible trend in Genomics-...

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) PR Newswire - Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Ge...

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical trial to be presented at a future medical meeting Large B-...